Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
Abstract Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic purposes. We here evaluate clinical outcomes according to ER levels in a monoinstitutional cohort of non-metastatic triple-negative breast can...
Guardado en:
Autores principales: | Maria Vittoria Dieci, Gaia Griguolo, Michele Bottosso, Vassilena Tsvetkova, Carlo Alberto Giorgi, Grazia Vernaci, Silvia Michieletto, Silvia Angelini, Alberto Marchet, Giulia Tasca, Elisa Genovesi, Enrico Cumerlato, Marcello Lo Mele, PierFranco Conte, Valentina Guarneri |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a5d10581508547cdb6d83e4a415f9496 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Federica Miglietta, et al.
Publicado: (2021) -
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Gaia Griguolo, et al.
Publicado: (2021) -
Temporal determinants of tumour response to neoadjuvant rectal radiotherapy.
por: Kendrick Koo, et al.
Publicado: (2021) -
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
por: Willard Wong, et al.
Publicado: (2021) -
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: G. Griguolo, et al.
Publicado: (2021)